# Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

> **NCT05803915** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 57 (estimated)

## Conditions studied

- Oral Squamous Cell Carcinoma

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT05803915
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2026-03-10
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05803915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05803915, "Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05803915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*